News, views and contacts from the global Drugdevelopment industry
 


Discovered and developed by Centocor, ustekinumab (CNTO 1275) is an investigational MAb with a novel dual mechanism of action. Its initial indication is for the treatment of moderate to severe plaque psoriasis.


Back to Project Details

cachename:Projectscachekey:rd287061489_125861108_rd221744618_-1334588407_rd-1665407042_-1874280820_rd-488908060_-173330816_